

3rd Immunonutrition Workshop, 21–24 October 2009, Girona, Spain

Effects of arachidonic and eicosapentaenoic acid derived eicosanoids on polymorphonuclear transmigration

J. J. Moreno

Departamento de Fisiología, Facultad de Farmacia, Universidad de Barcelona, Avda. Joan XXIII s/n, 08028 Barcelona and Instituto de Investigación en Nutrición y Seguridad Alimentaria (UB)

The *n*-3 polyunsaturated fatty acids contained in fish oil provide it with anti-inflammatory effects on different inflammatory diseases^(1,2). Several mechanisms can be involved in the influence of the degree of unsaturation of dietary fatty acids on the development of inflammatory diseases⁽³⁾. The beneficial effects of fish oil on inflammatory diseases have been attributed to the EPA/docosahexaenoic acid (DHA) content. EPA is also substrate for AA cascade enzymes, but induced the production of alternative eicosanoids such as 3-series prostanoids and 5-series leukotrienes that are considered to be less pro-inflammatory compared with AA metabolites. Thus, fish oil diet reduced AA mobilization and the subsequent prostaglandin (PG)E₂ synthesis⁽⁴⁾. However, the molecular basis of beneficial effect of EPA supplementation is poorly understood as well as the comparative biological effects of AA and EPA metabolites.

Leucocyte recruitment to inflamed areas is a pivotal event in the development of the inflammatory processes⁽⁵⁾. In this work, we studied the effects of PGE₂ and PGE₃ on endothelium permeability, the effects of leukotriene B₄ (LTB₄) and LTB₅ on endothelium permeability as well as mononuclear adhesion and migration.

Endothelial monolayer permeability to albumin was measured in ECV304 cell cultures using the Casnocha *et al.* methodology⁽⁶⁾. Polymorphonuclear (PMN) granulocytes were isolated from human blood samples using Histopaque-1077. ECV304 cell confluent cultures were plated with PMN in the presence of eicosanoids and allowed to attach at 37°C for 3 h. Non-adherent cells were removed, cultures were fixed and PMN adhered to ECV304 monolayer were counted under a phase-contrast microscope. LFA-1 and MAC-1, and E-selectin and ICAM-1 expression on PMN and ECV304 surface, respectively, were analysed with a fluorescein-activated cell sorter analyser using the corresponding antibodies to each adhesion molecule. PMN chemotaxis was measured using the modified Boyden chamber technique⁽⁷⁾ and a locomotion index was calculated using Maderazo and Woronick method⁽⁸⁾. Results are means ± SE of three independent experiments performed in duplicate. Student's *t* test was used to determine the significance.

Our results show that both prostaglandins (PGE₂ and PGE₃, 0.1–100 nM) increased *trans*-endothelial Evans blue-albumin (EBA) permeability in a concentration-dependent manner, reaching a maximum plateau effect at 100 nM. Interestingly, the effect of PGE₃ (increased 115 ± 3% *v.* control) (*P* < 0.001) was slight higher than PGE₂ (90 ± 4%) (*P* < 0.001) action and both were significantly antagonised by EP₁ (SC19200, 1 μM) and EP₂ (AH6809, 1 μM) antagonist, but not by EP₃ and EP₄ antagonist. LTB₄ and LTB₅ presented a slight effect on EBA extravasation (32 ± 2% and 21 ± 1.5%, respectively).

LTB₄ (1–100 nM) caused significant increases in the number of PMN cell adhering to endothelial cells (280 ± 13%–405 ± 21%) (*P* < 0.001 in all concentrations), whereas LTB₅ was not able to induce an appreciable effect. This effect of LTB₄ was mediated through the enhancement of adhesion molecules such as LFA-1 and MAC-1 on PMN surface and E-selectin and ICAM-1 expression on surface of endothelial cells. Finally, we observed that LTB₄ (10–100 nM) is a highly potent chemoattractant (migration index 1.25 ± 0.05 and 1.68 ± 0.1 *v.* migration index of 1 in control condition) (*P* < 0.05 and *P* < 0.001, respectively), whereas LTB₅ presents a weak effect (migration index of 1.15 ± 0.06 at 100 nM).

In conclusion, the summation of these differences in the LTB₄/LTB₅ effect on PMN transmigration may contribute to explain the beneficial impact of omega-3 in inflammatory processes.

This work was supported by the Ministerio de Ciencia y Tecnología (BFU2004-04960/BFI and BFU2007-61727/BFI) and the Generalitat de Catalunya (2005SGR0269).

1. Kremer JM (1996) *Lipids* **31**, S243–S247.
2. Soyland E, Funk J, Pajka G *et al.* (1993) *N Engl J Med* **328**, 1812–1816.
3. Moreno JJ & Mitjavila MT (2003) *J Nutr Biochem* **14**, 182–195.
4. Moreno JJ, Carbonell T, Sánchez T *et al.* (2001) *J Nutr* **131**, 2145–2149.
5. Lloret S & Moreno JJ (1995) *Biochem Pharmacol* **50**, 347–353.
6. Casnocha SA, Eskin SG, Hall ER *et al.* (1989) *J Appl Physiol* **67**, 1997–2005.
7. Boyden S (1962) *J Exp Med* **154**, 453–466.
8. Maderazo EG & Woronick CL (1978) *Clin Immunol Immunopathol* **11**, 196–211.